Keryx Share Price Tumbles Sharply On Phase III Failure Of Perifosine

With disappointing data in advanced colorectal cancer, Keryx is expected to abandon development of the Akt pathway inhibitor and focus all efforts on Phase III candidate Zerenex in ESRD.